Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00501241 · ClinicalTrials.gov registry record · Phase 2
Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation
A Phase 2 study, sponsored by Procter and Gamble.
- Terminated
- Registry status
- Phase 2
- Development phase
- 214
- Enrollment target
NCT00501241 is a Phase 2 study that was terminated before completion, run by Procter and Gamble. The registered enrollment target is 214 participants.
The verdict
NCT00501241, a Phase 2 study, was terminated before completion, sponsored by Procter and Gamble.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 214 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether ATI-7505 is effective in the treatment of chronic idiopathic constipation.
Interventions
- DRUG ATI-7505
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00501241
The ClinicalTrials.gov registry entry for NCT00501241 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Procter and Gamble, which has 70 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ATI-7505 is the first listed.
NCT00501241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00501241 about?
NCT00501241 is a clinical study titled "Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation". The purpose of this study is to determine whether ATI-7505 is effective in the treatment of chronic idiopathic constipation.
What is the current status of trial NCT00501241?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 214 participants. The study started on 2007-07. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00501241?
The interventions under investigation include: ATI-7505 (DRUG).
Who is sponsoring clinical trial NCT00501241?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.